The state’s life sciences trade association announced its slate of officers and board members for 2022, which include both returning and new appointees.
The election for this year’s BioNJ board officers and trustees took place before the organization’s Annual Board meeting on Feb. 2. The group added two new board members and three new advisors.
“While the last two years have been challenging as the industry, and the world, navigated a once-in-a-century health emergency, BioNJ’s board did not miss a beat,” said BioNJ President and CEO Debbie Hart in a prepared statement. “We are extremely grateful for the continued support and guidance of BioNJ’s dedicated board of trustees and advisors.
“Under the leadership of our chair, Will Lewis, we have continued to forge ahead, ensuring that New Jersey remains a robust life sciences ecosystem and that Patients have access to the right medicines at the right time,” she added.
Officers re-elected to the board
Chair Will Lewis, chair and CEO, Insmed;
Vice Chair Angela Bechan, vice president, Head of Communications & Corporate Social Responsibility North America, Sanofi; and
Secretary Michele Korfin, chief operating officer and chief commercial officer, Gamida Cell
Newly elected Oyster Point Pharma President and CEO Jeffrey Nau joins as treasurer.
Re-elected board members
· Mitzi Conners, executive director & head of operations, MRL Business Development & Licensing, Merck & Co.;
· Jayne Gershkowitz, chief patient advocate, Amicus Therapeutics;
· Christian Kopfli, CEO, Chromocell Corp.;
· Leigh Anne Leas, North America head of public policy, Novartis;
· Dr. Andrew Pecora, CEO and executive chairman, Outcomes Matter Innovations and president, Cellularity;
· Spiro Rombotis, president and CEO, Cyclacel Pharmaceuticals;
· Bob Smith, senior vice president, Global Gene Therapy Business and Early Commercial Development, Rare Disease Business Unit, Pfizer Biopharmaceuticals Group, Pfizer;
· Dr. Marco Taglietti, president and CEO, SCYNEXIS.
David Jiménez, president, Janssen Immunology, Janssen Pharmaceutical Cos., was newly elected to the board.
Rounding out the 2022 board of trustees are officers, Immediate Past Chair Christopher Schaber, president and CEO, Soligenix; and Hart. The remaining board members are Sol Barer, former Chairman and CEO, Celgene Corp. and chairman of the board, Teva Pharmaceutical Industries; Amadou Diarra, senior vice president, Global Policy & Government Affairs, Bristol Myers Squibb; Emer Leahy, president and CEO, PsychoGenics; Susan Levinson, CEO, BioAegis Therapeutics; John Maki, CEO, Bayesian Biotech; Anthony Marucci, founder, president, CEO and director, Celldex Therapeutics; Scott Megaffin, CEO, Adastra Pharmaceuticals; and Stuart Peltz, CEO, PTC Therapeutics.
New 2022 board advisors
· Technology Advisor Anu Gupta, senior partner, global leader, Enterprise Strategy, IBM Healthcare and Life Sciences;
· Legal Advisor Emilio Ragosa, partner and managing partner, Short Hills Office, DLA Piper; and
· Gregory Oakes.
The trio joins Kathleen Coviello, executive vice president for technology, life sciences & entrepreneurship, NJEDA; Dr. George Heinrich, vice chair and CEO, New Jersey Health Foundation and Foundation Venture Capital Group; Teresa Leste, strategy & analytics principal, Deloitte; Dr. Reynold Panettieri Jr., vice chancellor, Translational Medicine and Science; director, Rutgers Institute for Translational Medicine and Science; professor of Medicine, Rutgers University, New Brunswick, New Jersey & Emeritus Professor of Medicine, University of Pennsylvania; Emilio Ragosa, partner & managing partner, Short Hills office, DLA Piper; James Sapirstein, president and CEO, AzurRx BioPharma; and Brian Wilcomes, strategy & analytics principal, Deloitte & Touche.
“We welcome back our notable list of returning officers, board members and advisors and are thrilled to have the addition of two new board members and three new Advisors who are accomplished and respected industry leaders,” Hart added. “We look forward to working with all of them on what promises to be another busy year for BioNJ as we continue on our mission of helping our Members help Patients.”